PERTUSSIS IN ADULTS IMMUNOCOMPROMISED PATIENTS

Fiche du document

Auteur
Date

2017

Type de document
Périmètre
Langue
Identifiant
Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C95DB4F8CE605

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer



Sujets proches En

Pertussis

Citer ce document

J. GALANTAY, « PERTUSSIS IN ADULTS IMMUNOCOMPROMISED PATIENTS », Serveur académique Lausannois, ID : 10670/1.q2yjw8


Métriques


Partage / Export

Résumé 0

Pertussis (whooping cough) is a highly contagious upper respiratory tract infection, caused by Bordetella pertussis. This disease is particularly serious in infants, mostly in those younger than 6 months that have not, or only partially, been vaccinated. Since the introduction of a global anti- B. pertussis vaccination program, the incidence of pertussis has considerably decreased in the past few decades. In Switzerland, global letality rate is 0.05 deaths/1000 cases. This rate is four time higher in children from 0-5 years old (0.2 deaths/1000 cases), and even greater in infants under 3 months (10 deaths/1000 cases). (1) Causative agent of pertussis, Bordetella pertussis, is a gram-negative coccobacillus, whose humans are the only known reservoir. B. pertussis is spread by airborne droplets and binds to the epithelial cells of the trachea, bronchi and bronchioles thanks to its virulence factors. These include filamentous hemaglutinin, an adhesin that promotes adhesion to ciliated respiratory epithelial cells and phagocytosis by macrophages in view to upgrade bacterial survival, Pertussis toxin, a factor promoting systemic effects, such as lymphocytosis and adenylate cyclase toxin, inhibing anti-bacterial functions of innate cells. (2)

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en